Sequential chemotherapy with cisplatin/gemcitabine (CG) followed by mitoxantrone/methotrexate/mitomycin (MMM) in patients with malignant pleural mesothelioma. A multicenter Italian Phase II Study (SITMP1)

Lung Cancer

Volumn 52, Issue 2, 2006, Pages 199-206

  Pinto, Carmine ^a   Marino, Antonella ^a   Manzini, Vincenzo De Pangher ^b   Benedetti, Giovanni ^c   Galetta, Domenico ^d   Mazzanti, Paola ^e   Del Conte, Guido ^f   dell'Amore, Davide ^g   Piana, Edera ^a   Giaquinta, Stefania ^a   Lopez, Massimo ^h   Martoni, Andrea ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Civic Hospital   (Italy)

^c BELLARIA HOSPITAL   (Italy)

^d NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^e Torrette Hospital   (Italy)

^f Maggiore Hospital   (Italy)

^g MORGAGNI PIERANTONI HOSPITAL   (Italy)

^h REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Cisplatin gemcitabine; Mitoxantrone methotrexate mitomycin; Phase II study

Indexed keywords

CISPLATIN; GEFITINIB; GEMCITABINE; METHOTREXATE; MITOMYCIN; MITOXANTRONE; NAVELBINE; OXALIPLATIN; PEMETREXED; RALTITREXED; THALIDOMIDE;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PAIN; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DYSPNEA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; MULTICENTER STUDY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; SYMPTOM; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEOXYCYTIDINE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; ITALY; MALE; MESOTHELIOMA; METHOTREXATE; MIDDLE AGED; MITOMYCIN; MITOXANTRONE; NEOPLASM STAGING; PLEURAL NEOPLASMS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33646002369     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2006.01.002     Document Type: Article

References (40)

1. Peto J., Decarli A., La Vecchia C., Levi F., and Negri E. The European mesothelioma epidemic. Br J Cancer 79 (1999) 666-672
2. Comba P., Di Paola M., Martuzzi M., and Pirastu R. Asbestos-related mortality in Italy: a geographical approach. Med Lav 88 (1997) 293-301
3. Nesti M., Marinaccio A., and Chellini E. Malignant mesothelioma in Italy, 1997. Am J Ind Med 45 (2004) 55-62
4. Marinaccio A., and Nesti M. Analysis of survival of mesothelioma cases in the Italian Register. Eur J Cancer 39 (2003) 1290-1295
5. Spirtas R., Connelly R., and Tucker M. Survival patterns for malignant mesothelioma: the SEER experience. Int J Cancer 41 (1988) 525-530
6. Leigh J., Rogers J., Ferguson A.D., Mulder H.B., Ackad M., and Thompson R. Lung asbestos fiber content and mesothelioma cell type, site and survival. Cancer 68 (1991) 135-141
7. Tomek S., Emri S., Krejcy K., and Manegold C. Chemotherapy for malignant pleural mesothelioma: past results and recent developments. Br J Cancer 88 (2003) 167-174
8. Steele J.P.C., and Klabatsa A. Chemotherapy options and new advances in malignant pleural mesothelioma. Ann Oncol 16 (2005) 345-351
9. Peters G.J., Bergman A.M., Ruiz van Haperen V.W., Veerman G., Kujper C.M., and Braakhuis B.J. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 22 (1995) 72-79
10. Byrne M.J., Davidson J.A., Musk A.W., Dewar J., van Hazel G., Buck M., et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol 17 (1999) 25-30
11. Van Haarst J.M.W., Baas P., Manegold C., Schouwink J.H., Burgers J.A., de Bruin H.G., et al. Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer 86 (2002) 342-345
12. Nowak A.K., Byrne M.J., Williamson R., Ryan G., Segal A., Fielding D., et al. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer 87 (2002) 491-496
13. Castagneto B., Zai S., Dongiovanni V., Manzin E., Clerico M., and Botta M. Cisplatin and gemcitabine in malignant pleural mesothelioma: a phase II study. Proc Am Soc Clin Oncol 22 (2003) 2637a
14. Pinto C., Marino A., Guaraldi M., Melotti B., Piana E., Martoni A., et al. Combination chemotherapy with mitoxantrone, methotrexate and mitomycin (MMM regimen) in malignant pleural mesothelioma: a phase II study. Am J Clin Oncol 24 1 (2001) 143-147
15. Miller A.B., Hoogstraten B., Staquet M., and Winkler A. Reporting results of cancer treatment. Cancer 47 (1981) 207-214
16. Pannuti F., Lelli G., Rossi A.P., and Lapucci L. Il protocollo terapeutico in clinica oncologica. In: Pannuti F. (Ed). Trattato di Clinica Oncologica vol. I (1984), Padua, Piccin 231-288
17. Simon R. Optimal two-stage design for phase II clinical trials. Control Clin Trials 10 (1989) 1-10
18. Kaplan E.L., and Meier P. Non-parametric estimation from incomplete observation. J Am Stat Assoc 53 (1958) 457-481
19. International Mesothelioma Interest Group. A proposed new international TNM staging system for malignant pleural mesothelioma. Chest 108 (1995) 1122-1128
20. Baas P. Chemotherapy for malignant mesothelioma: from doxorubicin to vinorelbine. Semin Oncol 29 (2002) 62-69
21. Mintzer D.M., Kelsen D., Frimmer D., Heelan R., and Gralla R. Phase II of high-dose cisplatin in patients with malignant mesothelioma. Cancer Treat Rep 69 (1985) 711-712
22. Zidar B.L., Green S., Pierce H.I., Roach R.W., Balcerzak S.P., and Miltello L. A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: a Southwest Oncology Group Study. Invest New Drugs 6 (1988) 223-226
23. Vogelzang N.J., Rusthoven J.J., Symanowski J., Denham C., Kaukel E., Ruffie P., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21 (2003) 2636-2644
24. van Meerbeeck J.P., Manegold C., Gaafar R., van Klaveren R.J., Vincent M., Legrand C., et al. A randomized phase III trial of cisplatin with or without raltitrexed in patients (pts) with malignant pleural mesothelioma (MPM): an intergroup study of the EORTC Lung Cancer Group and NCIC. Proc Am Soc Clin Oncol 23 (2004) 7021a
25. Steele J.P.C., Shamash J., Evans M.T., Gower N.H., Tischkowitz M.D., and Rudd R.M. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 18 (2000) 3912-3917
26. Bischoff H.G., Manegold C., Knopp M., Blatter J., and Drings P. Gemcitabine (Gemzar) may reduce tumor load and tumor associated symptoms in malignant pleural mesothelioma. Proc Am Soc Clin Oncol 17 (1998) 464a
27. van Meerbeeck J.P., Baas P., Debruyne C., Groen H.J., Manegold C., Ardizzoni A., et al. A phase II study of gemcitabine in patients with malignant pleural mesothelioma. Cancer 85 (1999) 2577-2582
28. Kindler H.L., Millard F., and Herndon II J.E. Gemcitabine for malignant mesothelioma: a phase II trial by the cancer and leukemia group B. Lung Cancer 31 (2001) 311-317
29. Solheim O.P., Saeter G., Finnanger A.M., and Stenwig A.E. High dose methotrexate in the treatment of malignant mesothelioma of the pleura A phase II study. Br J Cancer 65 (1992) 956-960
30. ®) in malignant pleural mesothelioma: an EORTC phase II study (08992). Eur J Cancer 39 (2003) 353-357
31. Scagliotti G.V., Shin D.M., Kindler H.L., Vasconcelles M.J., Keppler U., Manegold C., et al. Phase II study of pemetrexed with and without folic acid and Vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 21 (2003) 1556-1561
32. Ardizzoni A., Rosso R., Salvati F., Fusco V., Cinquegrana A., De Palma M., et al. Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma: an Italian Lung Cancer Task Force (FONICAP) phase II study. Cancer 67 (1991) 2984-2987
33. Chahinian A.P., Antman K., Goutsou M., Corson J.M., Suzuki Y., Modeas C., et al. Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the cancer and leukemia group B. J Clin Oncol 11 (1993) 1159-1165
34. Fizazi K., Doubre H., Le Chevalier T., Riviere A., Viala J., Daniel C., et al. Combination of Raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study. J Clin Oncol 21 (2003) 349-354
35. Fennell Dean A., Steele J.P.C., Shamash J., Sheaff M.T., Evans M.T., Goonewardene T.I., et al. Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma. Lung Cancer 47 (2005) 277-281
36. Schutte W., Blankenburg T., Lauerwald K., Schreiber J., Bork I., Wollscgkaeger B., et al. A multicenter phase II study of gemcitabine and oxaliplatin for malignant pleural mesothelioma. Clin Lung Cancer 4 (2003) 294-297
37. Strizzi L., Catalano A., Vianale G., Orecchia S., Casalini A., Tassi G., et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 193 (2001) 468-475
38. Kindler HL, Karrison T, Lu C, Gandara DR, Stevenson J, Krug L, et al. A multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo in patients (pts) with malignant mesothelioma (MM). Proc Am Soc Clin Oncol 2005;24:7019a [abstract].
39. Favaretto A.G., Aversa S.M.L., Paccagnella A., De Pangher Manzini V., Palmisano V., Oniga F., et al. Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study. Cancer 97 (2003) 2791-2797
40. Martoni A., Marino A., Sperandi F., Giaquinta S., Di Fabio F., Melotti B., et al. Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer. Eur J Cancer 41 (2005) 81-92